Baidu
map

葛兰素史克在美国召回非处方减肥药Alli

2014-03-28 佚名 生物谷

北京时间3月28日凌晨消息,英国制药商葛兰素史克周四宣布,由于部分批次可能被篡改,包含了一种非正宗的产品,正在从美国以及波多黎各零售商处自愿召回所有的Alli减肥产品。 葛兰素史克在声明中说,收到来自七个州消费者就Alli的药瓶中装有不是Alli产品的片剂和胶囊的查询要求。在这些消费者投诉中,Alli减肥产品的瓶中发现有多种不同形状和颜色的片剂及胶囊。其中的一些药物没有标签,防伪封印也不是正宗的

北京时间3月28日凌晨消息,英国制药商葛兰素史克周四宣布,由于部分批次可能被篡改,包含了一种非正宗的产品,正在从美国以及波多黎各零售商处自愿召回所有的Alli减肥产品。

葛兰素史克在声明中说,收到来自七个州消费者就Alli的药瓶中装有不是Alli产品的片剂和胶囊的查询要求。在这些消费者投诉中,Alli减肥产品的瓶中发现有多种不同形状和颜色的片剂及胶囊。其中的一些药物没有标签,防伪封印也不是正宗的。Alli减肥药使用绿松石颜色的胶囊,胶囊中部暗蓝色条纹区有60 Orlistat的字样。

葛兰素史克北美消费者健康保健集团总裁科林-麦肯齐(Colin Mackenzie)说,“安全一直是我们的第一要务,我们正在要求零售商和药房立即将所有Alli减肥产品撤出他们的货架。”

葛兰素史克说,正在进行一次调查,并就相关事宜知会了美国联邦食品和药物管理局。

葛兰素史克在2007年隆重推出了Alli减肥产品,并为其花费了大笔营销预算,将其作为可能有10亿美元年销售额的重磅产品大肆推广。但是该产品从那以后面对包括制造环节产能不足造成供应短缺在内的很多问题,迫使公司延迟了产品的销售。

Alli是唯一获得联邦食品和药物管理局批准的非处方减肥产品,其工作原理是阻止胃肠吸收来自食物的脂肪。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819198, encodeId=9540181919855, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Wed May 21 05:20:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286149, encodeId=3d57128614926, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315735, encodeId=e4e31315e3505, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328853, encodeId=fda5132885380, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489242, encodeId=54f4148924234, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819198, encodeId=9540181919855, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Wed May 21 05:20:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286149, encodeId=3d57128614926, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315735, encodeId=e4e31315e3505, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328853, encodeId=fda5132885380, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489242, encodeId=54f4148924234, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819198, encodeId=9540181919855, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Wed May 21 05:20:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286149, encodeId=3d57128614926, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315735, encodeId=e4e31315e3505, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328853, encodeId=fda5132885380, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489242, encodeId=54f4148924234, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819198, encodeId=9540181919855, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Wed May 21 05:20:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286149, encodeId=3d57128614926, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315735, encodeId=e4e31315e3505, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328853, encodeId=fda5132885380, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489242, encodeId=54f4148924234, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=)]
    2014-03-30 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1819198, encodeId=9540181919855, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Wed May 21 05:20:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286149, encodeId=3d57128614926, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315735, encodeId=e4e31315e3505, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328853, encodeId=fda5132885380, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489242, encodeId=54f4148924234, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Sun Mar 30 05:20:00 CST 2014, time=2014-03-30, status=1, ipAttribution=)]

相关资讯

葛兰素史克(GSK)中国区运营几乎瘫痪 业内人士:土壤坏了

 葛兰素史克公司(简称GSK)事件被曝光至今已有一个月时间,该公司涉嫌严重经济犯罪的情况也在不断的被披露。美国《纽约时报》近日称,葛兰素史克中国研发中心违背药物临床试验的程序———即产品开始人体试验后才有动物实验报告。  《经济参考报》记者从各种渠道了解到,目前葛兰素史克公司中国区运营几乎瘫痪。很多人士都质疑,葛兰素史克公司之后,还有多少跨国药企将被调查?葛兰素史克公司“行贿门”事件是单独的企业行

公安部:葛兰素史克(GSK)在华行贿被立案 高管被查

  因涉嫌严重经济犯罪   葛兰素史克(中国)投资有限公司部分高管被公安机关立案侦查   根据国家相关部门提供的线索,日前,公安部统一组织指挥湖南长沙、上海和河南郑州等地公安机关对葛兰素史克(中国)投资有限公司 〔GlaxoSmithKline(China)InvestmentCo.Ltd,英文简称为GSK〕部分高管涉嫌严重经济犯罪依法立案侦查。   公安机关现已查明,作为大型

葛兰素史克取消医药代表销售目标

腾讯财经报道:据英国报道,葛兰素史克公司在中国陷入贿赂丑闻之后,为了修复医药代表形象并改革销售工作方式,该公司将取消医药代表的个人销售目标。近年来,人们对整个医药行业的过度营销日益担忧。去年,美国对医药公司的违规营销行为进行了一系列调查,罚款高达破纪录的30亿美元。周一提交给葛兰素史克公司高管的一份计划显示,该公司将取消医药代表与医生用药数量挂钩的奖金。相反,该公司将被销售人员奖金与病患照顾方面的

葛兰素史克叫停回扣式售药 停止向医生提供药品宣讲费

12月17日,深陷“贿赂门”的英国制药大鳄葛兰素史克(GSK)宣布,从2014年起,公司将针对销售人员推行全新的薪酬体系,医药代表的薪酬将不再与销 售指标挂钩。GSK还将停止向医生提供药品宣讲费,停止直接资助医生参加医学会议。不过有业内人士认为,GSK的新规只是为了使公司不成为直接行贿主体, 依然无法避免“以销售业绩论英雄”。GSK表示,新的医药代表薪酬方案中将不再出现个人销售指标。取而代之的是,

葛兰素史克两新药证实可延长皮肤癌患者生命

两种针对黑素瘤皮肤癌的新药物取得初步试验结果。相比传统化学疗法,新药可有效阻止或延缓癌细胞扩散,延长患者生命。 这两种靶向药物名为Dabrafenib和Trametinib,由英国葛兰素史克公司研制,已分别结束初步临床试验,与传统化疗作比对。 研制方3日在美国临床肿瘤学会芝加哥会议上发布临床试验结果。 322名黑素瘤皮肤癌晚期患者参与Trametinib项目试验,其中214人使用Tramet

葛兰素史克HIV新药Tivicay获欧盟批准

葛兰素史克(GSK)、辉瑞(Pfizer)、盐野义(Shionogi)共同成立的HIV/AIDS合资企业ViiV Healthcare 1月21日宣布,HIV新药Tivicay(dolutegravir,50mg片剂)获欧盟委员会(EC)批准,联合其他抗逆转录病毒药物用于HIV成人感染者和12岁以上青少年感染者的治疗。 Tivicay的获批,是基于4个关键性III期临床试验(SPRING-2、S

Baidu
map
Baidu
map
Baidu
map